Ambulatory Blood Pressure Monitoring to Diagnose and Manage Hypertension.


Journal

Hypertension (Dallas, Tex. : 1979)
ISSN: 1524-4563
Titre abrégé: Hypertension
Pays: United States
ID NLM: 7906255

Informations de publication

Date de publication:
02 2021
Historique:
pubmed: 5 1 2021
medline: 11 8 2021
entrez: 4 1 2021
Statut: ppublish

Résumé

This review portrays how ambulatory blood pressure (BP) monitoring was established and recommended as the method of choice for the assessment of BP and for the rational use of antihypertensive drugs. To establish much-needed diagnostic ambulatory BP thresholds, initial statistical approaches evolved into longitudinal studies of patients and populations, which demonstrated that cardiovascular complications are more closely associated with 24-hour and nighttime BP than with office BP. Studies cross-classifying individuals based on ambulatory and office BP thresholds identified white-coat hypertension, an elevated office BP in the presence of ambulatory normotension as a low-risk condition, whereas its counterpart, masked hypertension, carries a hazard almost as high as ambulatory combined with office hypertension. What clinically matters most is the level of the 24-hour and the nighttime BP, while other BP indexes derived from 24-hour ambulatory BP recordings, on top of the 24-hour and nighttime BP level, add little to risk stratification or hypertension management. Ambulatory BP monitoring is cost-effective. Ambulatory and home BP monitoring are complimentary approaches. Their interchangeability provides great versatility in the clinical implementation of out-of-office BP measurement. We are still waiting for evidence from randomized clinical trials to prove that out-of-office BP monitoring is superior to office BP in adjusting antihypertensive drug treatment and in the prevention of cardiovascular complications. A starting research line, the development of a standardized validation protocol for wearable BP monitoring devices, might facilitate the clinical applicability of ambulatory BP monitoring.

Identifiants

pubmed: 33390042
doi: 10.1161/HYPERTENSIONAHA.120.14591
pmc: PMC7803442
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

254-264

Références

Hypertension. 2011 Jan;57(1):3-10
pubmed: 21079049
Conf Proc IEEE Eng Med Biol Soc. 2004;2004:5384-7
pubmed: 17271560
Hypertension. 2017 Oct;70(4):676-682
pubmed: 28847889
Hypertension. 2013 May;61(5):964-71
pubmed: 23478096
Sci Rep. 2020 Jul 15;10(1):11685
pubmed: 32669581
Hypertension. 2014 Nov;64(5):1073-9
pubmed: 25185130
J Hypertens Suppl. 1994;12(7):S1-12
pubmed: 7769499
Am J Hypertens. 2011 Jan;24(1):52-8
pubmed: 20847724
J Am Coll Cardiol. 2016 Nov 8;68(19):2044-2046
pubmed: 27810042
Hypertension. 2012 Mar;59(3):564-71
pubmed: 22252396
JAMA. 1999 Aug 11;282(6):539-46
pubmed: 10450715
JAMA Intern Med. 2019 Mar 1;179(3):351-362
pubmed: 30715088
Circulation. 2017 Jun 20;135(25):2470-2480
pubmed: 28428231
Eur Heart J. 2013 Jul;34(28):2159-219
pubmed: 23771844
J Hypertens. 2007 Nov;25(11):2280-5
pubmed: 17921823
Am J Hypertens. 2017 May 1;30(5):453-463
pubmed: 28052877
Am J Hypertens. 1991 Mar;4(3 Pt 1):234-8
pubmed: 2043300
JAMA. 1983 May 27;249(20):2792-8
pubmed: 6842787
Hypertension. 2017 Jan;69(1):128-135
pubmed: 27821618
Hypertension. 2019 Jan;73(1):33-38
pubmed: 30571569
Hypertension. 2005 Feb;45(2):240-5
pubmed: 15596571
JAMA. 1988 Jan 8;259(2):225-8
pubmed: 3336140
Am J Hypertens. 1999 Nov;12(11 Pt 1):1149-57
pubmed: 10604495
Hypertension. 2014 Nov;64(5):935-42
pubmed: 25135185
Am J Hypertens. 2016 Jun;29(6):737-46
pubmed: 26476084
Am J Cardiol. 1991 Apr 1;67(8):723-7
pubmed: 1826069
Hypertension. 2019 Oct;74(4):776-783
pubmed: 31378104
Lancet. 2002 Dec 14;360(9349):1903-13
pubmed: 12493255
Circulation. 2007 Apr 24;115(16):2145-52
pubmed: 17420350
Hypertension. 2015 Jun;65(6):1170-9; discussion 1179
pubmed: 25916728
J Hum Hypertens. 2005 Oct;19(10):801-7
pubmed: 15959536
Am J Hypertens. 2016 Mar;29(3):326-31
pubmed: 26150543
Am J Hypertens. 1997 Nov;10(11):1201-7
pubmed: 9397237
Hypertension. 2019 Dec;74(6):1333-1342
pubmed: 31630575
J Am Coll Cardiol. 2016 Nov 8;68(19):2033-2043
pubmed: 27810041
Hypertens Res. 2012 Nov;35(11):1102-10
pubmed: 22895063
Ann Intern Med. 2019 Jun 18;170(12):853-862
pubmed: 31181575
Am J Hypertens. 1996 Jan;9(1):1-11
pubmed: 8834700
Hypertension. 2006 Jan;47(1):29-34
pubmed: 16344364
Am Heart J. 1988 Oct;116(4):1152-4
pubmed: 3177190
N Engl J Med. 2003 Jun 12;348(24):2407-15
pubmed: 12802026
Lancet. 1988 Aug 13;2(8607):397
pubmed: 2899801
Clin Exp Hypertens A. 1985;7(2-3):279-81
pubmed: 4039992
Am J Hypertens. 2014 Jul;27(7):956-65
pubmed: 24572704
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
Lancet. 2011 Oct 1;378(9798):1219-30
pubmed: 21868086
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Hypertension. 2019 May;73(5):e35-e66
pubmed: 30827125
Hypertension. 2005 Jul;46(1):156-61
pubmed: 15939805
Hypertension. 2014 Feb;63(2):229-37
pubmed: 24324050
J Hypertens. 2007 Aug;25(8):1554-64
pubmed: 17620947
Lancet. 2003 May 10;361(9369):1629-41
pubmed: 12747893
J Clin Hypertens (Greenwich). 2012 Dec;14(12):836-47
pubmed: 23205750
JAMA. 2019 Aug 6;322(5):409-420
pubmed: 31386134
Hypertension. 2006 May;47(5):846-53
pubmed: 16567588
Am J Hypertens. 2013 May;26(5):665-72
pubmed: 23391621
Hypertension. 2019 Jan;73(1):121-131
pubmed: 30571548
JAMA. 2014 Aug 27;312(8):799-808
pubmed: 25157723
J Hypertens. 2007 Dec;25(12):2406-12
pubmed: 17984661
Hypertension. 1994 Dec;24(6):793-801
pubmed: 7995639
J Hypertens. 2010 Oct;28(10):2036-45
pubmed: 20520575
Hypertension. 2010 Apr;55(4):1040-8
pubmed: 20212273
BMJ. 2010 Apr 14;340:c1104
pubmed: 20392760
JAMA. 1982 Feb 19;247(7):992-6
pubmed: 7057592
Lancet. 2007 Oct 6;370(9594):1219-29
pubmed: 17920917
Blood Press Monit. 2009 Oct;14(5):185-9
pubmed: 19641455
Hypertension. 2012 Nov;60(5):1138-47
pubmed: 23071126
Hypertension. 2007 Jun;49(6):1235-41
pubmed: 17389258
Hypertension. 1984 Jul-Aug;6(4):574-8
pubmed: 6235190

Auteurs

Qi-Fang Huang (QF)

From the Department of Cardiovascular Medicine, Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital (Q.-F.H., Y.L.), Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Wen-Yi Yang (WY)

Department of Cardiology, Shanghai General Hospital (W.-Y.Y), Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Kei Asayama (K)

Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (K.A.).
Tohoku Institute for Management of Blood Pressure, Sendai, Japan (K.A.).
Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (K.A., Z.-Y.Z., L.T., J.A.S).

Zhen-Yu Zhang (ZY)

Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (K.A., Z.-Y.Z., L.T., J.A.S).

Lutgarde Thijs (L)

Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (K.A., Z.-Y.Z., L.T., J.A.S).

Yan Li (Y)

From the Department of Cardiovascular Medicine, Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital (Q.-F.H., Y.L.), Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Eoin O'Brien (E)

Conway Institute, University College Dublin, Ireland (E.O.B.).

Jan A Staessen (JA)

Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (K.A., Z.-Y.Z., L.T., J.A.S).
Research Institute Alliance for the Promotion of Preventive Medicine (www.appremed.org), Mechelen, Belgium (J.A.S).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH